抗CD25抗体达利珠单抗在一名成人噬血细胞性淋巴组织细胞增生症患者中的成功应用。
Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.
作者信息
Olin Rebecca L, Nichols Kim E, Naghashpour Mojdeh, Wasik Mariusz, Shelly Brenda, Stadtmauer Edward A, Vogl Dan T
机构信息
Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
出版信息
Am J Hematol. 2008 Sep;83(9):747-9. doi: 10.1002/ajh.21236.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare and severe inflammatory disorder marked by abnormal cytotoxic T and natural killer cell activity, resulting in impaired clearance of pathogen, excessive cytokine production, and continued immune system activation. Soluble IL-2 receptor (sIL-2R or sCD25) is typically elevated in HLH and can serve as a marker of disease activity, although its role in the pathophysiology of the disease is unclear. Here we present a case of an adult patient with steroid-dependent HLH who was treated successfully with daclizumab, a monoclonal anti-CD25 antibody, allowing successful withdrawal of steroid therapy without an increase in symptoms.
摘要
噬血细胞性淋巴组织细胞增生症（HLH）是一种罕见且严重的炎症性疾病，其特征为细胞毒性T细胞和自然杀伤细胞活性异常，导致病原体清除受损、细胞因子过度产生以及免疫系统持续激活。可溶性白细胞介素-2受体（sIL-2R或sCD25）在HLH中通常会升高，可作为疾病活动的标志物，尽管其在该疾病病理生理学中的作用尚不清楚。在此，我们报告一例成年类固醇依赖型HLH患者，该患者接受抗CD25单克隆抗体达利珠单抗治疗成功，得以成功停用类固醇疗法且未出现症状加重。
相似文献
1
Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.抗CD25抗体达利珠单抗在一名成人噬血细胞性淋巴组织细胞增生症患者中的成功应用。
Am J Hematol. 2008 Sep;83(9):747-9. doi: 10.1002/ajh.21236.
2
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.抗CD25抗体达利珠单抗在抑制多发性硬化症炎症及稳定疾病进展方面的作用
Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.
3
Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.接受抗CD25抗体治疗患者的T细胞亚群监测。
Transplant Proc. 2004 Mar;36(2 Suppl):487S-491S. doi: 10.1016/j.transproceed.2004.01.071.
4
Lymphocyte-depleted Hodgkin lymphoma complicating hemophagocytic lymphohistiocytosis as an initial manifestation: a case report and review of the literature.以噬血细胞性淋巴组织细胞增生症为首发表现并伴有淋巴细胞消减的霍奇金淋巴瘤：一例报告及文献复习
Intern Med. 2012;51(21):3067-72. doi: 10.2169/internalmedicine.51.8275. Epub 2012 Nov 1.
5
Successful treatment of cerebral vasculitis in an HIV-positive patient with anti-CD25 treatment.采用抗CD25治疗成功治愈一名HIV阳性患者的脑血管炎。
Ann Rheum Dis. 2006 Dec;65(12):1677-8. doi: 10.1136/ard.2005.044867.
6
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.使用缩肽及其与针对CD25的未修饰达利珠单抗联合用药对成年T细胞白血病小鼠模型进行有效治疗。
Blood. 2009 Feb 5;113(6):1287-93. doi: 10.1182/blood-2008-04-149658. Epub 2008 Oct 23.
7
Successful treatment with daclizumab of refractory anaplastic lymphoma.用达利珠单抗成功治疗难治性间变性淋巴瘤。
Pediatr Blood Cancer. 2009 Dec;53(6):1130-1. doi: 10.1002/pbc.22177.
8
The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.在缺乏病理证据时，治疗前F-18-FDG PET-CT在淋巴瘤相关噬血细胞性淋巴组织细胞增生症中的意义。
J Cancer Res Clin Oncol. 2016 Apr;142(4):859-71. doi: 10.1007/s00432-015-2094-z. Epub 2015 Dec 15.
9
Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.
Med Pediatr Oncol. 2002 Feb;38(2):141-2. doi: 10.1002/mpo.1294.
10
Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.达克珠单抗降低急性肾移植排斥反应。达克珠单抗双药治疗研究组。
Transplantation. 1999 Jan 15;67(1):110-5. doi: 10.1097/00007890-199901150-00019.
引用本文的文献
1
The History of Macrophage Activation Syndrome in Autoimmune Diseases.自身免疫性疾病中巨噬细胞活化综合征的历史。
Adv Exp Med Biol. 2024;1448:21-31. doi: 10.1007/978-3-031-59815-9_3.
2
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.继发性噬血细胞性淋巴组织细胞增多症/巨噬细胞活化综合征的免疫病理学及潜在治疗策略：转化医学视角
Exp Mol Med. 2024 Mar;56(3):559-569. doi: 10.1038/s12276-024-01182-6. Epub 2024 Mar 6.
3
Advances and challenges of immunotherapies in NK/T cell lymphomas.NK/T细胞淋巴瘤免疫治疗的进展与挑战
iScience. 2023 Oct 12;26(11):108192. doi: 10.1016/j.isci.2023.108192. eCollection 2023 Nov 17.
4
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study.sCD25 作为成人 HLH 患者的独立不良预后因素：一项多中心回顾性研究的结果。
Blood Adv. 2023 Mar 14;7(5):832-844. doi: 10.1182/bloodadvances.2022007953.
5
Screening of hemophagocytic lymphohistiocytosis in children with severe sepsis in pediatric intensive care.在儿科重症监护病房中对严重脓毒症患儿进行噬血细胞性淋巴组织细胞增生症的筛查。
Sci Prog. 2021 Jul-Sep;104(3):368504211044042. doi: 10.1177/00368504211044042.
6
[Research progress of lymphoma associated hemophagocytic syndrome].[淋巴瘤相关噬血细胞综合征的研究进展]
Zhonghua Xue Ye Xue Za Zhi. 2020 Sep 14;41(9):788-792. doi: 10.3760/cma.j.issn.0253-2727.2020.09.019.
7
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.芦可替尼联合多柔比星、依托泊苷和地塞米松治疗淋巴瘤相关噬血细胞综合征。
J Cancer Res Clin Oncol. 2020 Nov;146(11):3063-3074. doi: 10.1007/s00432-020-03301-y. Epub 2020 Jul 2.
8
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.帕博利珠单抗诱导的噬血细胞性淋巴组织细胞增生症：一项免疫治疗挑战。
Cancers Head Neck. 2020 Feb 3;5:3. doi: 10.1186/s41199-020-0050-3. eCollection 2020.
9
Takotsubo cardiomyopathy secondary to haemophagocytic lymphohistiocytosis in HIV patients: a comprehensive review.HIV患者噬血细胞性淋巴组织细胞增生症继发的应激性心肌病：一项综述
BMJ Case Rep. 2019 Apr 23;12(4):e226599. doi: 10.1136/bcr-2018-226599.
10
Novel mutations of STXBP2 and LYST associated with adult haemophagocytic lymphohistiocytosis with Epstein-Barr virus infection: a case report.STXBP2 和 LYST 相关的新型突变与 EBV 感染相关的成人噬血细胞性淋巴组织细胞增生症：一例报告。
BMC Med Genet. 2019 Feb 19;20(1):34. doi: 10.1186/s12881-019-0765-3.
本文引用的文献
1
Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children.
Haematologica. 2008 Feb;93(2):291-4. doi: 10.3324/haematol.11704.
2
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.抗 Tac 单抗（达利珠单抗，赛尼哌）在白血病、自身免疫性疾病治疗及同种异体移植排斥反应预防中的应用：25 年个人历程
J Clin Immunol. 2007 Jan;27(1):1-18. doi: 10.1007/s10875-006-9060-0. Epub 2007 Jan 11.
3
Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy.
J Clin Rheumatol. 2001 Aug;7(4):252-6. doi: 10.1097/00124743-200108000-00013.
4
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.HLH-2004：噬血细胞性淋巴组织细胞增生症的诊断与治疗指南。
Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039.
5
Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives.噬血细胞性淋巴组织细胞增生症：诊断、病理生理学、治疗及未来展望
Ann Med. 2006;38(1):20-31. doi: 10.1080/07853890500465189.
6
Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis.英夫利昔单抗治疗难治性噬血细胞性淋巴组织细胞增生症取得成功。
Am J Hematol. 2006 Jan;81(1):59-61. doi: 10.1002/ajh.20462.
7
8
Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.
Med Pediatr Oncol. 2002 Feb;38(2):141-2. doi: 10.1002/mpo.1294.
9
Etanercept in the treatment of macrophage activation syndrome.依那西普治疗巨噬细胞活化综合征
J Rheumatol. 2001 Sep;28(9):2120-4.
10
Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis.
Blood. 1995 Dec 15;86(12):4706-7.
Zotero 插件